Search Results - therapeuticarea+%3e+rare+%2f+neglected+diseases

9 Results

Sort By:

A Key Advancement for Human Norovirus Research and Reverse Genetics

The HEK293T/T7 cell line is a novel development in virology research, particularly for studying human noroviruses. This cell line expresses the T7 RNA polymerase, a key enzyme used in reverse genetics systems. Unlike existing technologies, the HEK293T/T7 cell line offers the unique advantage of being able to produce functional T7 RNA polymerase, which...

Published: 12/10/2024 | Inventor(s): Carlos Sandoval-Jaime, Stanislav Sosnovtsev

Keywords(s):

Category(s): Application > Therapeutics, Application > Vaccines, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Human Cell Lines, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare / Neglected Diseases

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...

Published: 10/28/2024 | Inventor(s): Stephen Leppla, Shihui Liu, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Christopher Bachran, Damilola Phillips, Henning Hansen, Sarah Arnett, Clinton Leysath

Keywords(s): Against, AMOUNTS, Anthrax, AnthraxToxins, ANTIGEN, B, CA1BXX, CB1AXX, CB1BXX, CB1XXX, CB3CXX, CBXXXX, Cells, Cell-Surface, CMG2, COMPLEMENTARY, CONTAIN, Containing, CXXXXX, Cytolethal, Distending, EFFICACY, Efficient, ENGINEERED, exclusively, Exploiting, FELINE, FELINE Leukemia, FORM, Fusion, fusion proteins, Having, High, IC2-PA, Identifying, Improved, Leppla, Listed LPM McCue as of 4/15/2015, MARKER, Metallo..., MULTIMERIC, Mutated, Nature, Octamers, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, Protein, proteins, SOLID, SPECIFICALLY, Specificity, Strong, TARGET, Targeting, That, THERAPY, toxin, TOXINS, tumor, Types, UAXXXX, VARIANTS, VASCULATURE, VETERINARY

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases

Small-Molecule Inhibitors of Human Galactokinase for the Treatment of Galactosemia and Cancers

Lactose, found in dairy products and other foods, is comprised of two simple sugars, glucose and galactose. In galactosemia, where galactose is not properly metabolized, build-up of toxic compounds, such as galactose-1-phosphate, can lead to liver disease, renal failure, cataracts, brain damage, and even death if this disorder is left untreated. Currently,...

Published: 10/28/2024 | Inventor(s): Matthew Boxer

Keywords(s): AKT, CANCER, CB7XXX, CBXXXX, CXXXXX, Galactokinase, Galactose, Galactosemia, IBXXXX, Inhibitors, IXXXXX, lactose, Metabolism, PTEN, rare disease, small molecule, UAXXXX

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases, Application > Research Materials

Multivalent Vaccines for Rabies Virus and Filoviruses

No vaccine candidates against Ebola virus (EBOV) or Marburg virus (MARV) are nearing licensure and the need to develop a safe and efficacious vaccine against filoviruses continues. Whereas several preclinical vaccine candidates against EBOV or MARV exist, their further development is a major challenge based on safety concerns, pre-existing vector immunity,...

Published: 10/28/2024 | Inventor(s): Jason Paragas, Reed Johnson, Peter Jahrling, Joseph Blaney

Keywords(s): Against, Bivalent, Confer, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, DDXXXX, Dual, DXXXXX, Ebola, Ebola virus disease, INACTIVATED, Live-Attenuated, Marburg hemorrhagic fever, Protection, rabies, That, UAXXXX, vaccines, Viruses

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Research Materials, TherapeuticArea > Rare / Neglected Diseases

Compounds That Treat Malaria and Prevent Malaria Transmission

Malaria is the single leading cause of death, especially among children, in the developing world. Malaria is caused by infection with parasites of the genus Plasmodium, transmitted by mosquitos. In addition to transmission, vital steps in the parasite lifecycle occur in the mosquito host. The invention offered for licensing relates to therapeutic compounds...

Published: 10/28/2024 | Inventor(s): Jing Yuan, Sittiporn Pattaradilokrat, Ruili Huang, Ronald Johnson, Dipak Raj, Xin-zhuan Su

Keywords(s): ANTIMALARIAL, DB2XXX, DBXXXX, Discovery, DRUGS, DXXXXX, Malaria (Plasmodium sp.), Potential, UBXXXX, UXXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare / Neglected Diseases

Full-Length Infectious cDNA Clones of Tick Borne Flavivirus

The tick-borne encephalitis virus complex of flavivirus family includes tick-borne encephalitis (TBEV), Kyasanur forest disease, Langat, Louping ill, Negishi, Omsk hemorrhagic fever and Povassan viruses. These viruses are endemic throughout most of the Northern Hemisphere and except for Langat, cause human disease of varying severity that can have...

Published: 10/28/2024 | Inventor(s): Robert Chanock (Estate), Alexander Pletnev

Keywords(s): Borne, cDNA, CLONES, DC5BXX, DC5XXX, DCXXXX, DXXXXX, Flavivirus, FULL-LENGTH, Hemorrhagic fever, INFECTIOUS, Omsk hemorrhagic fever, Patent Category - Biotechnology, Q fever, SACGHS DNA Patent Initial Set, TICK, Tick-borne encephalitis, UAXXXX

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare / Neglected Diseases

TTP as a Regulator of GM-CSF mRNA Deadenylation and Stability

The disclosed invention provides materials and methods to treat granulocytopenia (low white cell count in the blood) which is characterized by a reduced number of granulocytes (relative) or an absence of granulocytes (absolute). This condition is commonly associated with cancer chemotherapy, but is seen less frequently in a number of conditions including...

Published: 10/28/2024 | Inventor(s): Wi Lai, Perry Blackshear, Ester Carballo

Keywords(s): Aplastic anemia, Deadenylation, Duke DNA Project, GM-CSF, Granulocytopenia, IB6XXX, IBXXXX, IXXXXX, REGULATOR, STABILITY, Systemic lupus erythematosus, TTP, UA1XXX

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Reproductive Health, Application > Research Materials, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Rare / Neglected Diseases

Method of Diagnosing Multidrug Resistant Tuberculosis

The invention can be used to develop tests that are much more rapid than conventional tests for determining drug resistance. It relates to the discovery that a putative gene of Mycobacterium tuberculosis (MTb) with no previously identified function is responsible for the ability of the bacteria to activate a class of second line thioamide drugs used...

Published: 10/28/2024 | Inventor(s): Andrea Debarber, Khisimuzi Mdluli, Clifton Barry

Keywords(s): DA3XXX, DAXXXX, DB3XXX, DBXXXX, DIAGNOSING, Duke DNA Project, DXXXXX, Methods, Multidrug, RESISTANT, TUBERCULOSIS, Tuberculosis (Mycobacterium tuberculosis), UA1XXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare / Neglected Diseases, Application > Diagnostics

ApoA-1 Mimetic Peptides Promoting Lipid Efflux from Cells for Treatment of Vascular Disorders

This invention involves ApoA-1 mimetic peptides with multiple amphipathic alpha-helical domains that promote lipid efflux from cells and are useful in the treatment and prevention of dyslipidemic, inflammatory and vascular disorders. IND-enabling studies for one of the peptides, named Fx-5A, are completed in preparation for an IND filing at the FDA,...

Published: 10/28/2024 | Inventor(s): Edward Neufeld, Fairwell Thomas, H. Bryan Brewer, Stephen Demosky, John Stonik, Marcelo Amar, Alan Remaley

Keywords(s): (4)r syndrome, 3-@hydroxyacyl-coa dehydrogenase deficiency, AMPHIPATHIC, assay, Atherosclerosis., C syndrome, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, COMPOSITION, G syndrome, HAD deficiency, HELICAL, HIS deficiency, Histidinemia, Hyperlipoproteinemia, Hypertelorism with esophageal abnormality and hypospadias, IA1XXX, IAXXXX, IXXXXX, Listed LPM Nguyen-Antczak as of 4/15/2015, Multi-domain, N syndrome, Patent Category - Biotechnology, Peptides, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, R(6) syndrome, R(7) syndrome, Syndrome X, System, treatment, UA1XXX, VDXXXX, VHXXXX, W syndrome, W syndrome; Syndrome W, WJXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Cardiology, TherapeuticArea > Endocrinology, Application > Therapeutics, TherapeuticArea > Rare / Neglected Diseases, Application > Research Materials, Application > Diagnostics